Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Health care utilization and cost among pediatric patients receiving unrelated donor allogeneic hematopoietic cell transplantation

Bone Marrow Transplantation volume 54, pages 691–699 (2019)Cite this article

Subjects

Abstract

The costs associated with allogeneic hematopoietic cell transplantation (alloHCT) are high. Differences in costs and healthcare utilization among potential donor sources for alloHCT are not well characterized in pediatric recipients of alloHCT. One potential reason for these high costs could be the donor source of hematopoietic cells. In this retrospective study, inpatient costs, outpatient costs, and markers of healthcare utilization associated with unrelated donor alloHCT for malignant and non-malignant disease were analyzed for 131 pediatric patients during the first year post-transplant, for whom the donor sources were 38% umbilical cord blood (UCB), 14% unmanipulated peripheral blood stem cell (PBSC), 26% bone marrow (BM), and 22% PBSC with CD-34 selection. The median cost per day survived (through day +365) was lowest for patients receiving PBSC with CD-34 selection $926 (322–5316) as compared to UCB $1918 (491–107,93), unmanipulated PBSC $1516 (630–27,516), and BM $1205 (506–11,181) (p = 0.010). For non-malignant alloHCT, UCB had the highest costs per day survived $1530 (491–793) and PBSC with CD-34 selection had the lowest at $482 (322–3092) (p < 0.001). In a multivariable model for costs per day survived, high-risk disease (p = 0.009) and graft failure (p < 0.001) were significantly associated with higher cost and alloHCT between 2010 and 2015 as compared to 2005 and 2009 (p = 0.017) was significantly associated with lower cost per day survived. This study illustrates important differences in cost and healthcare utilization among the different donor sources used for unrelated alloHCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

References

  1. Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the US registry. New Engl J Med. 2014;371:339–48.

    Article  CAS  Google Scholar 

  2. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303:1617–24.

    Article  CAS  Google Scholar 

  3. Stranges, E. (Thomson Reuters), Russo, CA. (Thomson Reuters), and Friedman, B. (AHRQ). Procedures with the Most Rapidly Increasing Hospital Costs, 2004–2007. HCUP Statistical Brief #82. December 2009. Agency for Healthcare Research and Quality, Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb82.pdf

  4. Gratwohl A, Baldomero H, Schwendener A, Gratwohl M, Urbano-Ispizua A, Frauendorfer K. Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe—impact of cost considerations. Leukemia. 2007;21:383–7.

    Article  CAS  Google Scholar 

  5. Khera N, Chang YH, Hashmi S, Slack J, Beebe T, Roy V, et al. Financial burden in recipients of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20:1375–81.

    Article  Google Scholar 

  6. Khera N, Zeliadt SB, Lee SJ. Economics of hematopoietic cell transplantation. Blood. 2012;120:1545–51.

    Article  CAS  Google Scholar 

  7. Bhella S, Majhail NS, Betcher J, Costa LJ, Daly A, Dandoy CE et al. American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group’s List of five tests and treatments to question in blood and marrow transplantation. Biol Blood Marrow Transplant. 2018;24:909–13.

  8. Maziarz RT, Hao Y, Guerin A, Gauthier G, Gauthier-Loiselle M, Thomas SK et al. Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2018;59:1133–42.

    Article  Google Scholar 

  9. Mullin, Emily. Why a trailblazing gene therapy is being pulled off the market. MIT Technol Rev. 2017. www.technologyreview.com/s/604252/the-worlds-most-expensive-medicine-is-being-pulled-from-the-market/.

  10. Diep PP, Melberg HO, Brinch L, Buechner J, Fløisand Y, Gedde-Dahl T et al. Cost per quality-adjusted life year: cost-utility of allogeneic hematopoietic stem cell transplantation in Norway. Bone Marrow Transplant. 2018;53:657–60.

    Article  Google Scholar 

  11. Majhail NS, Mothukuri JM, MacMillan ML, Verneris MR, Orchard PJ, Wagner JE, et al. Costs of pediatric allogeneic hematopoietic‐cell transplantation. Pediatr Blood Cancer. 2010;54:138–43.

    Article  Google Scholar 

  12. Majhail NS, Brunstein CG, McAvoy S, DeFor TE, Al-Hazzouri A, Setubal D, et al. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant. 2008;14:985–92.

    Article  CAS  Google Scholar 

  13. Glucksberg HR, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestation of graft-versus host disease in human recipients of marrow HLA matched sibling donors. Transplantation. 1974;18:295–304.

    Article  CAS  Google Scholar 

  14. McGuinn C, Geyer MB, Jin Z, Garvin JH, Satwani P, Bradley MB, et al. Pilot trial of risk‐adapted cyclophosphamide intensity based conditioning and HLA matched sibling and unrelated cord blood stem cell transplantation in newly diagnosed pediatric and adolescent recipients with acquired severe aplastic anemia. Pediatr Blood Cancer. 2014;61:1289–94.

    Article  CAS  Google Scholar 

  15. Rustia E, Violago L, Jin Z, Foca MD, Kahn JM, Arnold S, et al. Risk factors and utility of a risk-based algorithm for monitoring cytomegalovirus, Epstein-Barr virus, and adenovirus infections in pediatric recipients after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22:1646–53.

    Article  Google Scholar 

  16. Bordon V, Padalko E, Benoit Y, Dhooge C, Laureys G. Incidence, kinetics, and risk factors of Epstein–Barr virus viremia in pediatric patients after allogeneic stem cell transplantation. Pediatr Transplant. 2012;16:144–50.

    Article  CAS  Google Scholar 

  17. Mynarek M, Ganzenmueller T, Mueller-Heine A, Mielke C, Gonnermann A, Beier R, et al. Patient, virus, and treatment-related risk factors in pediatric adenovirus infection after stem cell transplantation: results of a routine monitoring program. Biol Blood Marrow Transplant. 2014;20:250–6.

    Article  Google Scholar 

  18. Pediatric Analytic Solutions [Internet]. Pediatric Health Information System [cited 2017 Oct 4]. https://www.childrenshospitals.org/programs-and-services/data-analytics-and-research/pediatric-analytic-solutions/pediatric-health-information-system

  19. Consumer Price Index [Internet]. U.S. Bureau of Labor Statistics. U.S. Bureau of Labor Statistics [cited 2017 Sep 4]. https://data.bls.gov/pdq/SurveyOutputServlet

  20. Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transplant. 2009;15:564–73.

    Article  Google Scholar 

  21. Satwani P, Jin Z, Duffy D, Morris E, Bhatia M, Garvin JH, et al. Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients. Biol Blood Marrow Transplant. 2013;19:552–61.

    Article  Google Scholar 

  22. D’Souza A, Lee S, Zhu X, Pasquini M. Current use and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2017;23:1417–21.

    Article  Google Scholar 

  23. Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, et al. Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant. 2015;50:476.

    Article  CAS  Google Scholar 

  24. Broder MS, Quock TP, Chang E, Reddy SR, Agarwal-Hashmi R, Arai S, et al. The cost of hematopoietic stem-cell transplantation in the United States. Am Health Drug Benefits. 2017;10:366.

    PubMed  PubMed Central  Google Scholar 

  25. Majhail NS, Mau LW, Denzen EM, Arneson TJ. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database. Bone Marrow Transplant. 2013;48:294.

    Article  CAS  Google Scholar 

  26. Shulman DS, London WB, Guo D, Duncan CN, Lehmann LE. Incidence and causes of hospital readmission in pediatric patients after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21:913–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Columbia University Medical Center, New York, NY, USA

    Wallace Bourgeois

  2. Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Department of Pediatrics, Columbia University Medical Center, New York, NY, USA

    Angela Ricci, Diane George, Monica Bhatia, James Garvin & Prakash Satwani

  3. Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, USA

    Zhezhen Jin

  4. Children’s Hospital Association, Lenexa, KS, USA

    Matt Hall

Authors
  1. Wallace Bourgeois
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angela Ricci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhezhen Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matt Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Diane George
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Monica Bhatia
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. James Garvin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Prakash Satwani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Prakash Satwani.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bourgeois, W., Ricci, A., Jin, Z. et al. Health care utilization and cost among pediatric patients receiving unrelated donor allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 54, 691–699 (2019). https://doi.org/10.1038/s41409-018-0308-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0308-0

This article is cited by

Search

Advanced search

Quick links